Jazz Pharmaceuticals plc
Jazz Pharmaceuticals Reports Strong 2023 Financial Results and Provides 2024 Guidance
Summary
Jazz Pharmaceuticals plc announced strong financial results for the full year and fourth quarter of 2023, with total revenues of $3.8 billion and $1 billion respectively. Key product sales grew significantly, including Xywav, Epidiolex, and Rylaze. The company provided financial guidance for 2024, expecting double-digit percentage revenue growth across its key growth drivers. The full-year 2024 revenue guidance is between $4.0 and $4.2 billion.
Profitelligence Alerts
Get alerts for JAZZ
Be first to know when Jazz Pharmaceuticals plc files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to research, manufacture, and market drugs that address unmet medical needs, particularly in the fields of neuroscience, oncology, and sleep medicine. Jazz Pharmaceuticals has gained prominence for its innovative products such as Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia. Headquartered in Dublin, Ireland, the company operates extensively across North America and Europe, working to advance scientific research in pharmaceuticals. By prioritizing patient care and survival, Jazz Pharmaceuticals plays a significant role in the pharmaceutical industry with its commitment to developing novel therapies. Moreover, the company's strategic collaborations and acquisitions enable it to expand its product portfolio and impact the healthcare sector positively. Jazz Pharmaceuticals continues to be a key player in transforming patient care for complex conditions.
Official SEC Documents
Advertisement